Montserrat Rivero - Concepedia

Author

Montserrat Rivero

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas ORCID

Also Known As

J.L.F. Forcelledo, José Luis Cabriada, José L´zaro Pérez-Calle, L Bujanda, L De Castro, M Rivero, M Rivero Tirado, M. Rivero, M. Rivero Tirado, M. rivero

222

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Instituto de Investigación Marqués de Valdecilla Marqués de Valdecilla University Hospital Hospital Universitario de La Princesa Hospital Universitario Río Hortega

About

Montserrat Rivero is an author at Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas specializing in medicine, gastroenterology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	664
2	Gastroenterology	4	4	458
3	Epidemiology	2	2	31
4	Hepatology	2	2	102
5	Public Health	1	1	13

Montserrat Rivero

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Bruce E. Sands, Peter M. Irving, Timothy Hoops, The Lancet ImmunologyClinical TrialsGastroenterologyMaintenance TherapyBiological Therapy	2022	277
Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding Joaquín de la Peña, Enric Brullet, Eloy Sánchez, Hepatology	2005	210
Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial J Peña, Montserrat Rivero, Eloy Sánchez, Gastrointestinal Endoscopy VaricesEndovascular TechniqueVariceal HemorrhageVariceal LigationVascular Surgery	1999	109
Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study Carlos Chavarría, María José Casanova, María Chaparro, Journal of Crohn s and Colitis	2019	96
Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry María Chaparro, Ana Garre, Elena Ricart, Alimentary Pharmacology & Therapeutics	2018	95
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study María Chaparro, Ana Garre, Andrea Núñez Ortiz, Journal of Clinical Medicine	2021	92
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, Gastroenterology	2023	86
Plasma Leptin and TNF-α Levels in Chronic Hepatitis C Patients and Their Relationship to Hepatic Fibrosis Javier Crespo, Montserrat Rivero, Emilio Fábrega, Digestive Diseases and Sciences	2002	82
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis Carlos Taxonera, Cristina Rodríguez, Federico Bertoletti, Inflammatory Bowel Diseases	2017	80
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry María Chaparro, A Garre, Marisa Iborra, Journal of Crohn s and Colitis	2021	79

Page 1